Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

July 27, 2024

Study Completion Date

December 31, 2025

Conditions
HospicePsilocybinDemoralizationTerminal IllnessCancer-related Problem/ConditionPsychotherapyTerminal CancerCancer Terminal
Interventions
DRUG

Psilocybin

Oral, single administration, dosage 25 mg orally

BEHAVIORAL

Psychotherapy

The treatment regimen consists of a single administration of psilocybin orally combined with a supportive psychotherapy including 2 preparation sessions and 2 integration sessions

Trial Locations (1)

01923

Care Dimensions, Danvers

All Listed Sponsors
collaborator

Oppenheimer Family Psychosocial Oncology and Palliative Care Research Grants

UNKNOWN

collaborator

Usona Institute

OTHER

collaborator

Carey and Claudia Turnbull Family Foundation

UNKNOWN

collaborator

Heffter Research Institute

OTHER

collaborator

George Sarlo Foundation

UNKNOWN

collaborator

RiverStyx Foundation

OTHER

collaborator

Council on Spiritual Practices Fund at the San Francisco Foundation

UNKNOWN

collaborator

Nikean Foundation

UNKNOWN

collaborator

Jack Smith

UNKNOWN

lead

Yvan Beaussant, MD, MSci

OTHER